PRESS RELEASE
News
-
-
PRESS RELEASE
PGA Professional Nathalie Sheehan Joins Forces With XXIO, Becoming Newest Brand Ambassador
PGA Professional Nathalie Sheehan, recognized as one of golf's best young teachers in America, is joining XXIO® as their newest brand ambassador. She will collaborate with the XXIO team on video content and share her expertise in swing and golf fitness tips. Sheehan's teaching knowledge and ability to connect with golfers of all skill levels make her a valuable addition to the brand, and she is excited to show golfers the benefits of XXIO's lightweight equipment for players with moderate swing speeds. Follow XXIO on social media for future content with Nathalie. -
PRESS RELEASE
Fuller, Smith & Turner PLC: Director/PDMR Shareholding
Fuller, Smith & Turner PLC has announced a Director/PDMR Shareholding. The company has been notified that the Trustees of a family trust, in which the children of Sir James Fuller, Non-Executive Director, are beneficiaries, have agreed to purchase 74,627 'C' Ordinary Shares of 40p each at a price of £6.70 per share. For further details, refer to the PDMR dealing notification. This announcement complies with EU Market Abuse Regulation 596/2014 and UK domestic law. For enquiries, contact Rachel Spencer, Company Secretary at 020 8996 2073. -
PRESS RELEASE
ASRT INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Assertio Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP notifies Assertio Investors about a class action lawsuit regarding the company's securities between March 9, 2023, and November 8, 2023. The complaint involves the approval of generic versions of Assertio's primary pharmaceutical product and disappointing Q3 financial results. Investors who acquired Assertio securities during this period have until March 5, 2024, to serve as a lead plaintiff for the purported class. Contact Kaplan Fox for more information about the lead plaintiff process. -
PRESS RELEASE
The Ketamine Story: Transforming Treatment for Mood Disorders and Pain
Join a free webinar on February 5, 2024, at 6 PM PST, to explore the transformative role of ketamine in modern healthcare. The event titled 'The Ketamine Story: Transforming Treatment for Mood Disorders and Pain' features a panel of distinguished experts, including Drs. Sam Ko, Glareh Imani, and Ray Rivas, who will delve into the past, present, and future of ketamine therapy. This insightful webinar is essential for individuals interested in ketamine therapy, catering to a wide audience with varying levels of understanding in this transformative treatment. -
REGULATED PRESS RELEASE
Déclaration hebdomadaire d'opérations effectuées du 15 au 19 janvier 2024
-
REGULATED PRESS RELEASE
Disclosure of transactions in own shares on January 15 to January 19, 2024
-
PRESS RELEASE
Student Transportation Company Adopts School Bus Optimization Technology to Improve Operations and Safety
Palmer Bus, a major student transportation contractor in the Midwest, has signed a multi-year deal with Bytecurve to leverage the Bytecurve360 platform. This transformative technology suite aims to enhance dispatch, driver communications, and payroll management for the fleet of approximately 750 buses serving over 20 districts in Minnesota. The platform provides solutions for drag-and-drop dispatching, mobile app connectivity for drivers, absence management features, and real-time dashboard alerts, ultimately connecting data between routing software and GPS tracking. The CEO of Palmer Bus expressed confidence in Bytecurve's ability to revolutionize the bus transportation industry. -
PRESS RELEASE
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Dada Nexus Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - DADA
Rosen Law Firm, a global investor rights law firm, is reminding Dada Nexus Limited investors of the important March 11, 2024 lead plaintiff deadline in the securities class action. Investors may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. If you wish to serve as lead plaintiff, you must move the Court no later than March 11, 2024. The Rosen Law Firm encourages investors to select qualified counsel with a track record of success in leadership roles, and represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. -
PRESS RELEASE
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
The Rosen Law Firm, a global investor rights law firm, has announced the filing of a class action lawsuit against BioNTech SE. The lawsuit claims that BioNTech overstated demand for its COVID-19 vaccine and had accumulated excess inventory of raw materials. Investors who purchased BioNTech securities during the specified period may be entitled to compensation and are encouraged to seek legal counsel before the important deadline.
